Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - cukura diabēts, 2. tips - cukura diabēts - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

astrazeneca ab  - metformīns hidrohlorīds, saxagliptin hidrohlorīds - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - komboglyze ir norādīts, kā papildinājums diēta un fiziskā uzlabot glycaemic kontroles pieaugušiem pacientiem vecumā no 18 gadiem un vecāki ar 2. tipa cukura diabētu nepietiekami kontrolēta to maksimāli pieļaujamo devu metformīns vienatnē vai tiem, kas jau tiek apstrādāti ar kombinācija saxagliptin un metformīns kā atsevišķa tabletes. komboglyze tiek norādīta arī kombinācijā ar insulīnu i. trīskāršās kombinācijas terapija), kā palīglīdzekli, lai diētu un vingrinājumiem, lai uzlabotu glycaemic kontroles pieaugušo pacientiem, kuri ir 18 gadus veci un vecāki ar 2. tipa cukura diabēta, kad insulīna un metformīns vien nenodrošina pietiekamu kontroles glycaemic.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

astrazeneca ab - metformīns hidrohlorīds, saxagliptin, dapagliflozin - cukura diabēts, 2. tips - cukura diabēts - qtrilmet ir norādīts pieaugušajiem vecumā no 18 gadiem un vecāki ar 2. tipa cukura diabētu:lai uzlabotu glycaemic kontroles, ja metformīns ar vai bez sulfonilurīnvielas pamata (su) un vai nu saxagliptin vai dapagliflozin nenodrošina pietiekamu kontroles glycaemic. ja jau tiek ārstēti ar metformīnu un saxagliptin un dapagliflozin.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).

Latvija - latviešu - Zāļu valsts aģentūra

grindeks, as, latvia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg

Latvija - latviešu - Zāļu valsts aģentūra

grindeks, as, latvia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.